Sorg Elaine K.
SEC CIK 1832571 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | SVP, US Commercial Ops | 35.3K | — | $12.61M | 18 | 2021-08-23 | 2023-04-25 |
Most active insiders at ABBV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Siatis Perry C | EVP, GC AND Sec | — | $9.52M |
| 2 | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT Off | — | $8.18M |
| 3 | Purdue David Ryan | SVP, Ctrl | — | $1.22M |
| 4 | Crum Demetris D | EVP, Chief HR Off | — | — |
| 5 | Thakkar Roopal | EVP, CSO, R, D | — | — |
| 6 | Quaggin Susan E | Dir | — | — |
| 7 | Reents Scott T | EVP, CFO | — | — |
| 8 | Davis Jennifer L. | Dir | — | — |
| 9 | Stewart Jeffrey Ryan | EVP, Chief COMMERCIAL Off | — | — |
| 10 | MEYER MELODY B | Dir | — | — |
Sorg Elaine K. made no open-market trades at ABBV in the last 12 months.
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-27 | 2023-04-25 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | S - Sale+OE | $165.00 | -6,130 | 35.3K | -15% | -$1.01M |
| D | 2023-04-27 | 2023-04-25 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | M - OptEx | $144.54 | +6,130 | 41.5K | +17% | +$886.0K |
| M | 2023-04-19 | 2023-04-17 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | S - Sale | $161.67 | -7,499 | 35.8K | -17% | -$1.21M |
| D | 2023-04-05 | 2023-04-03 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | M - OptEx | $93.50 | +15.0K | 57.8K | +35% | +$1.40M |
| D | 2023-04-05 | 2023-04-03 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | S - Sale+OE | $160.03 | -15.0K | 42.8K | -26% | -$2.40M |
| D | 2023-03-02 | 2023-03-01 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | M - OptEx | $93.50 | +15.0K | 57.8K | +35% | +$1.40M |
| D | 2023-03-02 | 2023-02-28 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | F - Tax | $154.28 | -19.9K | 42.8K | -32% | -$3.06M |
| D | 2023-03-02 | 2023-03-01 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | S - Sale+OE | $155.00 | -15.0K | 42.8K | -26% | -$2.33M |
| DM | 2023-02-21 | 2023-02-16 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | A - Grant | $0.00 | +44.8K | 62.7K | +251% | $0 |
| DM | 2023-02-21 | 2023-02-21 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | S - Sale+OE | $151.04 | -15.3K | 71.1K | -18% | -$2.31M |
| D | 2023-02-21 | 2023-02-21 | ABBV | AbbVie | Sorg Elaine K. | SVP, US COMMERCIAL Ops | M - OptEx | $105.92 | +15.3K | 78.0K | +24% | +$1.62M |
| 2022-03-01 | 2022-02-25 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | F - Tax | $149.54 | -11.1K | 24.4K | -31% | -$1.66M | |
| M | 2022-03-01 | 2022-03-01 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | S - Sale | $148.28 | -6,484 | 22.0K | -23% | -$961.5K |
| DM | 2022-02-22 | 2022-02-17 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | A - Grant | $0.00 | +35.5K | 25.1K | New | $0 |
| 2021-12-14 | 2021-12-10 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | F - Tax | $124.15 | -5,137 | 6,458 | -44% | -$637.8K | |
| M | 2021-12-14 | 2021-12-13 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | S - Sale | $125.85 | -6,458 | 0 | -100% | -$812.7K |
| DM | 2021-08-25 | 2021-08-23 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | S - Sale+OE | $120.00 | -13.1K | 11.6K | -53% | -$1.57M |
| D | 2021-08-25 | 2021-08-23 | ABBV | AbbVie | Sorg Elaine K. | SVP, US Commercial Ops | M - OptEx | $114.36 | +7,080 | 18.7K | +61% | +$809.7K |
Purchase Sale Sale after option exercise All abbreviations